Haploidentical hematopoietic stem cells transplantation for the treatment of medulloblastoma One case report
10.3969/j.issn.1673-8225.2010.32.041
- VernacularTitle:单倍体相合造血干细胞移植治疗髓母细胞瘤1例
- Author:
Haiyan HU
;
Hongbo GUO
;
Bingyi WU
;
Lan DENG
;
Chaoyang SONG
;
Kunyuan GUO
- Publication Type:Journal Article
- From:
Chinese Journal of Tissue Engineering Research
2010;14(32):6073-6076
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND: Some reports demonstrated that, autoallergic or hematopoietic stem cells transplantation combined with chemotherapy received good outcomes in treating medulloblastoma, which can prolong survival time of patients. However, whether haploidentical hematopoietic stem cells transplantation can treat medulloblastoma remains poorly understood.OBJECTIVE: To firstly report a patient receiving haploidentical hematopoietic stem cells transplantation for treating medulloblastoma.METHODS: A terminal cancer patient with bone matastases successively received six lymphocyte transfusions from an unrelated donor combined with chemotherapy and three haploidentical hematopoietic stem cell transplantations.RESULTS AND CONCLUSION: The patient presented erythra, accompanied by fever, diarrhea and yellow brown liquid stools, which was considered as graft versus host disease, and treated by urbason, gammaglobulin, CellCept, Prograf, Basiliximab (anti-CD25 antibody), Infliximab (anti-tumor necrosis factor α antibody), effective antibacterial and supportive treatments. After that, the erythra and diarrhea were remised. But the patient died from cerebral hemorrhage. Allogeneic lymphocyte transfusion can kill or damage tumor cells, improve life quality, but the outcome is restrained for patient with a high tumor burden. Immunosuppressant, such as anti-CD25 antibody and anti-tumor necrosis factor α antibody should be timely used in consideration of allogeneic hematopoietic stem cell transplantation.
